News Sentiment

SLDB sentiment intelligence

Solid Biosciences LLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.42 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-3.9% over one week, +45.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Solid Biosciences (SLDB) Proxy filing Summary

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -3.9% Price reacting lower
Trend fit Trend active 45.9% over four weeks
Fair value 71.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 26
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 7
GlobeNewswire 4
Quartr 3
simplywall.st 3
Sahm 2
Simply Wall Street 2
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 13
Balance sheet 4
Regulatory and legal 2
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
Quartr Direct company coverage

Solid Biosciences (SLDB) Proxy filing Summary

Solid Biosciences (SLDB) has released its proxy filing summary, detailing proposals for its virtual annual meeting on June 10, 2026. Key items include the election of three Class II directors, ratification of an advisory appointment, approval of the external auditor, and an amend

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jul 2026 06:11
Source
Quartr
Quartr Direct company coverage

Solid Biosciences (SLDB) Registration filing Summary

This document summarizes Solid Biosciences' (SLDB) registration filing from March 2026, detailing the company's focus on gene therapy for rare neuromuscular and cardiac diseases. It highlights a $240 million private placement, the registration of 42.78 million shares for resale,

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 10:41
Source
Quartr
Quartr Direct company coverage

Solid Biosciences (SLDB) AGM 2026 Summary

This article summarizes Solid Biosciences' (SLDB) 2026 Annual General Meeting (AGM) held on June 12, 2026, as a virtual event. Key outcomes included the election of three Class II directors and the advisory ratification of a Class I director, with a quorum established at 86.57% o

Tone
Positive 70/100
Event
Market update
Published
13 Jul 2026 01:11
Source
Quartr
Sahm Direct company coverage

How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices

Solid Biosciences Inc. (SLDB) was recently added to several Russell growth indices, including the Russell 2000, 2500, 3000, 3000E, Microcap, and Small Cap Comp Growth indices. This inclusion is expected to increase the company's visibility to institutional investors and index-tra

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 23:11
Source
Sahm
Simply Wall Street Direct company coverage

Is Solid Biosciences (SLDB) Undervalued Following Its Russell Growth Index Additions?

Solid Biosciences (SLDB) has been added to several Russell growth indices following a significant share price increase. A Discounted Cash Flow (DCF) model by Simply Wall St suggests the stock is undervalued with a fair value of $140.99 per share compared to its current price of $

Tone
Positive 67/100
Event
Balance sheet
Published
08 Jul 2026 09:10
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Form 4 Solid Biosciences LLC For: 7 July By Investing.com

This article reports on a Form 4 filing by Solid Biosciences LLC for July 7, 2026. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The brief piece indicates that financial markets worldwide can access this information via Inv

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Director at Solid Biosciences (SLDB) converts 3,440 RSUs into shares

Solid Biosciences Inc. director Ian F. Smith converted 3,440 Restricted Stock Units (RSUs) into common stock on July 2, 2026, at a price of $0.00 per share. This transaction increased his direct holdings to 138,145 shares of Common Stock, with an additional 6,880 RSUs remaining.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:05
Source
Stock Titan
AD HOC NEWS Direct company coverage

Solid Biosciences updates gene therapy pipeline as investors watch clinical strategy

Solid Biosciences, a clinical-stage biotechnology company, is refining its gene therapy focus and clinical strategy for rare neuromuscular and cardiac diseases. The company, which is listed on Nasdaq, is centered on providing long-term treatment options for patients and relies on

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 15:40
Source
AD HOC NEWS
Simply Wall Street Direct company coverage

Does Solid Biosciences' (SLDB) Russell Index Debut Hint at a Turning Point in Its Growth Story?

Solid Biosciences Inc. (SLDB) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 3000 Growth. This inclusion is expected to increase institutional visibility and liquidity for the company's stock. While it could broad

Tone
Neutral 50/100
Event
Balance sheet
Published
03 Jul 2026 07:39
Source
Simply Wall Street
Seeking Alpha Direct company coverage

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences (SLDB) is transitioning from a Duchenne gene therapy focus to a broader multi-asset rare disease platform, supported by its $380.7M cash position funding operations into 2028. The company's SGT-003 program shows promising Phase 1/2 data for Duchenne, and new pro

Tone
Positive 71/100
Event
Balance sheet
Published
02 Jul 2026 11:40
Source
Seeking Alpha
www.marketscreener.com Direct company coverage

Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2000 Growth Benchmark

Solid Biosciences Inc. (NasdaqGS: SLDB), a life sciences company focused on genetic medicines for neuromuscular and cardiac diseases, has been included in the Russell 2000 Growth Benchmark. This addition follows its recent inclusion in the Russell 3000E Growth Benchmark and the S

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 11:12
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Microcap Growth Benchmark Index

Solid Biosciences Inc. (SLDB) has been added to the Russell Microcap Growth Benchmark Index, as reported on June 28, 2026. This inclusion highlights the company's progress and visibility within the biotechnology and medical research sector. Solid Biosciences specializes in develo

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 06:10
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of Solid Biosciences Inc. – NASDAQ:SLDB

This article provides financial information for Solid Biosciences Inc. (NASDAQ: SLDB), specifically focusing on its forward price-to-sales ratio. The content lists the company's financial overview within the context of the biotechnology sector.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 10:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Solid Biosciences Inc. – NASDAQ:SLDB

The article focuses on the "Price to earnings forward" metric for Solid Biosciences Inc. (NASDAQ: SLDB). It appears to be a truncated financial data page from TradingView, displaying the company's ticker, market status, and a navigation bar. The content does not elaborate on the

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

SLDB Forecast — Price Target — Prediction for 2027

This article provides a forecast for Solid Biosciences Inc. (SLDB) stock, detailing analyst price targets, historical stock performance, and financial data. It includes information on current stock price, market capitalization, earnings per share, revenue, and upcoming earnings d

Tone
Positive 76/100
Event
Earnings
Published
25 Jun 2026 20:11
Source
TradingView
TradingView Direct company coverage

Solid Biosciences Inc. Actuals & Estimates (NASDAQ:SLDB)

This article provides an overview of Solid Biosciences Inc. (NASDAQ: SLDB) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts for SLDB, notes recent earnings performance, and confirms the company's next earnings rep

Tone
Positive 70/100
Event
Earnings
Published
25 Jun 2026 18:11
Source
TradingView
Investing.com Canada Direct company coverage

Form 13D/A SOLID BIOSCIENCES INC. For: 24 June By Investing.com

This article announces the filing of Form 13D/A by SOLID BIOSCIENCES INC. on June 24th, as reported by Investing.com. It is a brief administrative notice regarding a regulatory filing related to the company. The text includes various market data and news unrelated to the main sub

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 07:10
Source
Investing.com Canada
Stock Titan Direct company coverage

RA Capital (NASDAQ: SLDB) boosts Solid Biosciences holding to 11.9% ownership

RA Capital Management and its affiliates have increased their beneficial ownership in Solid Biosciences Inc. (NASDAQ: SLDB) to 11.9%, now holding 12,036,126 shares of common stock. This increase follows recent purchases in June 2026, including 338,100 shares in open-market trades

Tone
Positive 65/100
Event
Market update
Published
24 Jun 2026 23:09
Source
Stock Titan
TradingKey Direct company coverage

Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis

Solid Biosciences Inc (SLDB) currently has a valuation score of 6.24, placing it in the bottom tier of the Biotechnology & Medical Research industry. Its P/E ratio stands at -4.33, reflecting a significant drop from its recent high. The company has not yet disclosed relevant data

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 10:11
Source
TradingKey
Timothy Sykes Direct company coverage

Solid Biosciences Jumps As H.C. Wainwright Lifts Price Target

Solid Biosciences (SLDB) saw its stock jump by 14.29% after H.C. Wainwright raised its price target from $20 to $25, reiterating a Buy rating due to encouraging updates on the SGT-212 gene therapy program for Friedreich's ataxia. Despite significant R&D spending and negative prof

Tone
Positive 70/100
Event
Analyst action
Published
21 Jun 2026 14:40
Source
Timothy Sykes
Sahm Direct company coverage

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Solid Biosciences (NASDAQ:SLDB) has a cash runway of about 2.2 years based on its March 2026 cash reserves and annual cash burn of US$173 million, though its cash burn increased by 61% over the last year. Despite this, analysts expect the company to reach cashflow breakeven in fo

Tone
Neutral 50/100
Event
Balance sheet
Published
20 Jun 2026 01:40
Source
Sahm